0001640455-19-000095.txt : 20191226 0001640455-19-000095.hdr.sgml : 20191226 20191226170812 ACCESSION NUMBER: 0001640455-19-000095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191223 FILED AS OF DATE: 20191226 DATE AS OF CHANGE: 20191226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MURRAY RICHARD /CA/ CENTRAL INDEX KEY: 0001242935 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 191311054 MAIL ADDRESS: STREET 1: 22643 WOODRIDGE CT CITY: CUPERTINO STATE: CA ZIP: 95014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_157739807365922.xml FORM 4 X0306 4 2019-12-23 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001242935 MURRAY RICHARD /CA/ C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2019-12-23 4 M 0 40000 0.48 A 134510 D Common Stock 2019-12-23 4 S 0 40000 8.37 D 94510 D Stock Option (Right to Buy) 0.48 2019-12-23 4 M 0 40000 0.48 D 2024-06-26 Common Stock 40000.0 785169 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019. The Reporting Person exercised no discretion with respect to these transactions. Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $8.15 to $8.55 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. 25% of the option shares vested and became exercisable on July 14, 2015 and the remainder of the option shares vested and became exercisable in 36 monthly installments thereafter. /s/ Kim C. Drapkin, Attorney-in-Fact 2019-12-26